<?xml version="1.0" encoding="UTF-8"?>
<p>Epidemiological evidence indicates that higher serum urate may lower Parkinson’s disease risk (
 <xref rid="fcaa031-B33" ref-type="bibr">Gao 
  <italic>et al.</italic>, 2016
 </xref>; 
 <xref rid="fcaa031-B96" ref-type="bibr">Wen 
  <italic>et al.</italic>, 2017
 </xref>). Four small MR studies have found a protective role of raised serum urate on Parkinson’s disease risk (
 <xref rid="fcaa031-B32" ref-type="bibr">Gao 
  <italic>et al.</italic>, 2013
 </xref>; 
 <xref rid="fcaa031-B37" ref-type="bibr">González-Aramburu 
  <italic>et al.</italic>, 2013
 </xref>), age of onset (
 <xref rid="fcaa031-B29" ref-type="bibr">Facheris 
  <italic>et al.</italic>, 2011
 </xref>) and progression to disability requiring dopaminergic treatment at 1 year (
 <xref rid="fcaa031-B80" ref-type="bibr">Simon 
  <italic>et al.</italic>, 2014
 </xref>). More recently, two considerably larger MR studies found no significant association between plasma urate and Parkinson’s disease risk (
 <xref rid="fcaa031-B53" ref-type="bibr">Kia 
  <italic>et al.</italic>, 2018
 </xref>; 
 <xref rid="fcaa031-B54" ref-type="bibr">Kobylecki 
  <italic>et al.</italic>, 2018
 </xref>).
</p>
